Neither medication is significantly harder to tolerate than the other
It may also benefit individuals with active lifestyles, those looking to support healthy metabolic function, or people interested in maintaining cardiovascular wellness as they age
However, direct comparisons require caution because: Trial lengths differed Dosing protocols differed Patient populations differed Long-term orforglipron data is still developing A 5% to 10% reduction in body weight can still produce clinically meaningful improvements in blood pressure, insulin sensitivity, mobility, and metabolic health
Starting doses are sub-therapeutic by design, existing to allow gastrointestinal adaptation, yet some patients get appetite reduction and modest weight loss even there
Your pace
Therefore, after SARS-CoV-2 infection, the immune system is up-regulated, promoting many different molecules that can act in the CNS by different pathways